Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
49.05 USD | +1.47% | +1.74% | +9.61% |
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 50% by 2026.
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 74.7 times its estimated earnings per share for the ongoing year.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+9.61% | 966M | C | ||
+5.89% | 32.93B | C | ||
+17.30% | 7.94B | C- | ||
+30.15% | 4.19B | B- | ||
-28.10% | 2.8B | C- | ||
-18.15% | 1.38B | B | ||
-33.33% | 1.17B | - | ||
-37.56% | 900M | - | ||
-26.41% | 839M | - | C+ | |
-19.89% | 687M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SLP Stock
- Ratings Simulations Plus, Inc.